Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 69Carcinoma, Neuroendocrine 26Pheochromocytoma 23Thyroid Cancer, Papillary 21Pituitary Neoplasms 21Thyroid Neoplasms 20Adrenocortical Carcinoma 18Paraganglioma 15Multiple Endocrine Neoplasia Type 1 12Sarcoma 11Neuroblastoma 11Small Cell Lung Carcinoma 10Neoplasms 10Melanoma 9Lung Neoplasms 9Carcinoid Tumor 9Adrenal Gland Neoplasms 9Adenoma, Islet Cell 9Pancreatic Neoplasms 8Gastro-enteropancreatic neuroendocrine tumor 8Carcinoma, Non-Small-Cell Lung 8Carcinoma, Medullary 8Adenocarcinoma, Follicular 8Thyroid Carcinoma, Anaplastic 7Ovarian Neoplasms 7Neoplasm Metastasis 7Cushing Syndrome 7Cholangiocarcinoma 7Central Nervous System Neoplasms 7Breast Neoplasms 7

Interventions

Lutetium-177 1Lutetium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Gastroenteropancreatic Neuroendocrine Tumor × Endocrine × 90 days × Clear all
NCT05884255 2026-05-19

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Recruiting
220 enrolled
EndocrineGastrointestinalNET

Advanced Gastroenteropancreatic Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡